Compare · GILD vs PHXM
GILD vs PHXM
Side-by-side comparison of Gilead Sciences Inc. (GILD) and PHAXIAM Therapeutics S.A.. (PHXM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PHXM operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $187.10B.
- GILD has hit the wire 16 times in the past 4 weeks while PHXM has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for PHXM).
- Company
- Gilead Sciences Inc.
- PHAXIAM Therapeutics S.A..
- Price
- -
- -
- Market cap
- $187.10B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2017
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 590 shares and covered exercise/tax liability with 285 shares, increasing direct ownership by 4% to 8,759 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,780 shares and covered exercise/tax liability with 4,230 shares, increasing direct ownership by 0.79% to 581,683 units (SEC Form 4)
- Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
- Chairman & CEO O'Day Daniel Patrick sold $2,229,592 worth of shares (15,000 units at $148.64) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 577,133 units (SEC Form 4)
Latest PHXM
- PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
- SEC Form 15F-12B filed by PHAXIAM Therapeutics S.A..
- PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
- SEC Form EFFECT filed by PHAXIAM Therapeutics S.A..
- SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
- SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
- SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
- SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
- SEC Form S-8 POS filed by PHAXIAM Therapeutics S.A..
- SEC Form POS AM filed by PHAXIAM Therapeutics S.A..